Grifols, S.A. (GRFS)
GRFSNASDAQ-GSBiotechnology: Pharmaceutical Preparations
$8.69
+0.2600 (+3.08%) today
Closed, Nov 9, 4:00 PM ET
- Market cap
- $5.97bn
- P/E
- –
- EPS, last 4 quarters
- –
- Dividend yield
- –
- Day range
- –
- 52-week range
- $6.96 to $9.77
- Average volume
- 624.7k
- Previous close
- $8.43
Analysts
1 coveringHold0 buy, 1 hold, 0 sell
Targets a year out average $9.00, +3.6% from here
Earnings
next estimate $0.3300Next report
Financials
No quarterly figures from the source.
News
8 latest- Grifols Q3 Net Profit Rises, Revenue Up 8.4%; On Track To Meet 2026 Guidance RTTNews · Nov 3, 2026
- Grifols (GRFS) Q3 2026 Earnings Call TranscriptThe Motley Fool · Nov 2, 2026
- Grifols Q3 Earnings Call HighlightsMarketBeat · Nov 2, 2026
- Are Options Traders Betting on a Big Move in Grifols Stock?Zacks · Oct 7, 2026
- GRFS vs. SDZNY: Which Stock Should Value Investors Buy Now?Zacks · Sep 24, 2026
- After Hours Most Active for Sep 23, 2026 : WBD, GRAB, NVDA, NIO, CMCSA, TTD, BMY, GRFS, PBR, RKT, RBLX, ONASDAQ.com · Sep 23, 2026
- GRFS or SDZNY: Which Is the Better Value Stock Right Now?Zacks · Sep 8, 2026
- Can Asceniv Help ADMA Stock Combat IG Market Challenges? Zacks · Aug 13, 2026
The company
Grifols is a global healthcare company founded in Barcelona in 1909 committed to improving the health and well-being of people around the world. A leader in essential plasma-derived medicines and transfusion medicine, the company develops, produces and provides innovative healthcare services and solutions in more than 110 countries. Patient needs and Grifols' ever-growing knowledge of many chronic, rare and prevalent conditions, at times life-threatening, drive the company's innovation in both plasma and other biopharmaceuticals to enhance quality of life. Grifols focuses on treating conditions centered on six core therapeutic areas: immunology, neurology, pulmonology, hematology, hepatology and intensive care. A pioneer in the plasma industry, Grifols continues to grow its network of donation centers, the world's most diversified with more than 400 across North America, Europe, Africa and the Middle East, and China.
- Sector
- Health Care
- Industry
- Biotechnology: Pharmaceutical Preparations
- Exchange
- NASDAQ-GS
- Region
- Europe
- Website
- grifols.com
Often looked at with it
Figures from Yahoo, Nasdaq (Zacks consensus) and Lighter. Stocks can be minutes behind. Nothing here is advice.